Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research
Autor: | James Shen, Mihaela C. Cristea, Scott Glaser, Christina Hsiao Wei, Daphne Stewart, Siamak Saadat, Edward Wang, Richard Li, Stephen J. Lee, Susan Shehayeb, Ernest S. Han, Thanh H. Dellinger, Sharon P. Wilczynski, Sariah Liu, Lorna Rodriguez-Rodriguez |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
epithelial ovarian cancer medicine.medical_specialty endocrine system diseases maintenance therapy lcsh:Medicine Translational research Review surgical debulking team medicine frontline treatment 03 medical and health sciences 0302 clinical medicine Maintenance therapy medicine Intensive care medicine Survival rate HIPEC business.industry BRCA mutation lcsh:R Cancer General Medicine genetics counseling medicine.disease female genital diseases and pregnancy complications adjuvant chemotherapy 030104 developmental biology Clinical research PARP inhibitor clinical research 030220 oncology & carcinogenesis Community practice Ovarian cancer business PIPAC adjuvant chemotherapy |
Zdroj: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 9, Iss 2830, p 2830 (2020) |
ISSN: | 2077-0383 |
Popis: | Epithelial ovarian cancer (EOC) is the most common histology of ovarian cancer defined as epithelial cancer derived from the ovaries, fallopian tubes, or primary peritoneum. It is the fifth most common cause of cancer-related death in women in the United States. Because of a lack of effective screening and non-specific symptoms, EOC is typically diagnosed at an advanced stage (FIGO stage III or IV) and approximately one third of patients have malignant ascites at initial presentation. The treatment of ovarian cancer consists of a combination of cytoreductive surgery and systemic chemotherapy. Despite the advances with new cytotoxic and targeted therapies, the five-year survival rate for all-stage EOC in the United States is 48.6%. Delivery of up-to-date guideline care and multidisciplinary team efforts are important drivers of overall survival. In this paper, we review our frontline management of EOC that relies on a multi-disciplinary approach drawing on clinical expertise and collaboration combined with community practice and cutting edge clinical and translational research. By optimizing partnerships through team medicine and clinical research, we combine our cancer center clinical expertise, community practice partnership, and clinical and translational research to understand the biology of this deadly disease, advance therapy and connect our patients with the optimal treatment that offers the best possible outcomes. |
Databáze: | OpenAIRE |
Externí odkaz: |